OLMA

Olema Pharmaceuticals, Inc. [OLMA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

OLMA Stock Summary

Top 10 Correlated ETFs

OLMA


Top 10 Correlated Stocks

OLMA


In the News

04:30 16 Apr 2024 OLMA

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

SAN FRANCISCO, April 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a panel on “Breast Cancer – Shifting an Entrenched Paradigm” at the 2024 CG Horizons in Oncology Virtual Conference on Monday, April 15, 2024, at 2:00 p.m. ET.

07:01 16 Apr 2024 OLMA

Olema Oncology to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company will participate in the following upcoming investor conferences:

04:01 16 Apr 2024 OLMA

Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that Sean P. Bohen, M.D., President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 9, 2024, at 5:15 p.m. PT (8:15 p.m. ET).

05:10 16 Apr 2024 OLMA

Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)

Presentations detailing initial Phase 1b clinical data for palazestrant in combination with ribociclib, a Poster Spotlight Session on Phase 2 clinical data for palazestrant in combination with palbociclib, and the OPERA-01 Phase 3 clinical trial in progress will be presented on Dec. 7, 2023

11:52 16 Apr 2024 OLMA

Olema Pharmaceuticals: Advancing On Multiple Fronts

Today, we revisit Olema Pharmaceuticals, Inc. for the first time in two years. Olema is a clinical-stage biotech company focused on developing therapies for women's cancers. Their primary product candidate, palazestrant, has been granted FDA Fast Track designation for the treatment of metastatic breast cancer. Palazestrant is advancing in development both as a potential monotherapy and as part of potential combination therapies.

02:17 16 Apr 2024 OLMA

Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why

Olema's (OLMA) shares surge on the successful development of its lead candidate in metastatic breast cancer indication.

04:27 16 Apr 2024 OLMA

Olema Oncology to Participate in Upcoming Investor Conferences in November

SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company will present at the following upcoming investor conferences in November:

10:33 16 Apr 2024 OLMA

Olema Pharmaceuticals, Inc. (OLMA) Is a Great Choice for 'Trend' Investors, Here's Why

Olema Pharmaceuticals, Inc. (OLMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

10:32 16 Apr 2024 OLMA

Here's Why Momentum in Olema Pharmaceuticals, Inc. (OLMA) Should Keep going

Olema Pharmaceuticals, Inc. (OLMA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

09:24 16 Apr 2024 OLMA

7 ‘Strong Buy' Biotech Stocks to Rejuvenate Your Portfolio

While the health innovation space presents wild risks, you could potentially swing the odds in your favor with strong buy biotech stocks. Specifically, these ideas represent publicly traded biotechnology firms that enjoy the highest possible consensus rating among Wall Street analysts.

OLMA Financial details

Company Rating
Neutral
Market Cap
607.23M
Income
-95.34M
Revenue
0
Book val./share
4.63
Cash/share
4.78
Dividend
-
Dividend %
-
Employees
74
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-5.73
Forward P/E
-4.04
PEG
3.41
P/S
-
P/B
1.95
P/C
2.26
P/FCF
-7.67
Quick Ratio
17.39
Current Ratio
17.66
Debt / Equity
0.01
LT Debt / Equity
0.01
-
-
EPS (TTM)
-2.13
EPS next Y
-2.67
EPS next Q
-0.56
EPS this Y
-16.41%
EPS next Y
25.52%
EPS next 5Y
-120.54%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
2.08%
-
-
-
-
SMA20
-8.33%
SMA50
-15.38%
SMA100
-31.25%
Inst Own
90.55%
Inst Trans
1%
ROA
-32%
ROE
-46%
ROC
-0.37%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
55.91M
Shs Float
48.58M
-
-
-
-
Target Price
24
52W Range
3.55-17.791
52W High
-36.53%
52W Low
+259.67%
RSI
44
Rel Volume
0.58
Avg Volume
811K
Volume
469.61K
Perf Week
0.84%
Perf Month
-25.89%
Perf Quarter
-1.01%
Perf Half Y
-14.57%
-
-
-
-
Beta
2.106
-
-
Volatility
0.3%, 1.01%
Prev Close
-0.64%
Price
10.79
Change
-5.85%

OLMA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.11-0.58-1.79-2.56-2.14
Operating cash flow per share
-0.08-0.51-1.28-2.05-1.85
Free cash flow per share
-0.08-0.51-1.32-2.06-1.85
Cash per share
08.6114.195.115.79
Book value per share
-0.268.67.24.945.61
Tangible book value per share
-0.268.67.24.945.61
Share holders equity per share
-0.268.67.24.945.61
Interest debt per share
00.020.080.060.05
Market cap
1.97B1.89B369.95M97.99M634.82M
Enterprise value
1.97B1.55B85.99M76.85M568.69M
P/E ratio
-456.05-83.03-5.22-0.96-6.57
Price to sales ratio
00000
POCF ratio
-638.86-95.13-7.3-1.19-7.58
PFCF ratio
-638.86-94.87-7.08-1.19-7.58
P/B Ratio
-185.85.591.30.52.5
PTB ratio
-185.85.591.30.52.5
EV to sales
00000
Enterprise value over EBITDA
-456.99-72.27-1.21-0.72-5.44
EV to operating cash flow
-638.83-78.09-1.7-0.94-6.79
EV to free cash flow
-638.83-77.87-1.65-0.93-6.79
Earnings yield
0-0.01-0.19-1.05-0.15
Free cash flow yield
0-0.01-0.14-0.84-0.13
Debt to equity
000.010.010.01
Debt to assets
000.010.010.01
Net debt to EBITDA
0.0215.773.990.20.63
Current ratio
0.0774.6231.8512.6212.33
Interest coverage
0-32.970299.690
Income quality
0.710.90.710.780.87
Dividend Yield
00000
Payout ratio
0-0.14000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
000.0300
Capex to revenue
00000
Capex to depreciation
0-5.09-9.66-1.020
Stock based compensation to revenue
00000
Graham number
0.810.5917.0516.8816.42
ROIC
0.41-0.07-0.24-0.52-0.41
Return on tangible assets
-32.7-0.07-0.24-0.48-0.35
Graham Net
-0.278.513.94.665.29
Working capital
-1.28M337.55M278.23M192.35M244.89M
Tangible asset value
-10.59M338.14M284.57M197.55M253.9M
Net current asset value
-10.62M337.55M275.87M190.8M243.46M
Invested capital
000.010.010.01
Average receivables
0065K224.5K496K
Average payables
525.5K827K371K198.5K1.54M
Average inventory
00-176.5K-336K-159.5K
Days sales outstanding
00000
Days payables outstanding
37.78K23.86K5.0582.332.61K
Days of inventory on hand
00-77.48-70.230
Receivables turnover
00000
Payables turnover
0.010.0272.34.430.14
Inventory turnover
00-4.71-5.20
ROE
0.41-0.07-0.25-0.52-0.38
Capex per share
00-0.04-0.010

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.63-0.67-0.49-0.48-0.49
Operating cash flow per share
-0.49-0.51-0.54-0.51-0.34
Free cash flow per share
-0.49-0.51-0.54-0.51-0.34
Cash per share
5.094.614.116.164.78
Book value per share
4.924.343.976.124.63
Tangible book value per share
4.924.343.976.124.63
Share holders equity per share
4.924.343.976.124.63
Interest debt per share
0.030.020.050.060.04
Market cap
98.46M140.03M367.7M555.47M768.62M
Enterprise value
77.32M101.4M334.75M440.68M702.5M
P/E ratio
-0.98-1.3-4.57-6.46-7.18
Price to sales ratio
00000
POCF ratio
-5-6.87-16.63-24.42-41.6
PFCF ratio
-4.95-6.87-16.63-24.42-41.6
P/B Ratio
0.50.82.282.023.03
PTB ratio
0.50.82.282.023.03
EV to sales
00000
Enterprise value over EBITDA
-2.84-3.43-15.57-18.95-23.16
EV to operating cash flow
-3.92-4.97-15.14-19.38-38.02
EV to free cash flow
-3.89-4.97-15.14-19.38-38.02
Earnings yield
-0.26-0.19-0.05-0.04-0.03
Free cash flow yield
-0.2-0.15-0.06-0.04-0.02
Debt to equity
0.010.010.010.010.01
Debt to assets
0.010.010.010.010.01
Net debt to EBITDA
0.781.31.534.942.18
Current ratio
12.629.7611.5617.6612.33
Interest coverage
21.6922.49000
Income quality
0.750.721.11.060.69
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.010000
Capex to revenue
00000
Capex to depreciation
-1.780000
Stock based compensation to revenue
00000
Graham number
8.328.076.648.117.14
ROIC
-0.13-0.16-0.12-0.08-0.12
Return on tangible assets
-0.12-0.14-0.11-0.07-0.1
Graham Net
4.644.093.775.824.37
Working capital
192.35M169.99M156.68M266.04M244.89M
Tangible asset value
197.55M174.98M161.58M275.13M253.9M
Net current asset value
190.8M168.6M155.47M264.34M243.46M
Invested capital
0.010.010.010.010.01
Average receivables
388K310.5K462K681K706.5K
Average payables
194K527.5K1.15M1.92M2.45M
Average inventory
802K-310.5K1.45M3.65M2.05M
Days sales outstanding
00000
Days payables outstanding
79.57143.54344.122.21K2.76K
Days of inventory on hand
-67.87-63.65678.924.09K0
Receivables turnover
00000
Payables turnover
1.130.630.260.040.03
Inventory turnover
-1.33-1.410.130.020
ROE
-0.13-0.15-0.12-0.08-0.11
Capex per share
00000

OLMA Frequently Asked Questions

What is Olema Pharmaceuticals, Inc. stock symbol ?

Olema Pharmaceuticals, Inc. is a US stock , located in San francisco of Ca and trading under the symbol OLMA

Is Olema Pharmaceuticals, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $24. The lowest prediction is $24 and the highest is $24

What is OLMA stock prediction ?

With a median analyst target price of $24, 1 stock analysts have made 1 forecasts in last 90 days. $24 is the lowest and $24 is the greatest projection.

What is Olema Pharmaceuticals, Inc. stock quote today ?

Olema Pharmaceuticals, Inc. stock price is $10.79 today.

Is Olema Pharmaceuticals, Inc. stock public?

Yes, Olema Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap